Exenatide-PD3 study did not meet its primary end point

[BlockRuys]

Trial participants learned from the lead investigator that the Exenatide-PD3 study did not meet its primary end point (this is the predetermined measure of success). The results indicate that there was no significant difference in the progression of motor symptoms between the treatment and placebo groups (those not taking active drug). There was also no difference between the groups with any of the other measures included in this trial.

cureparkinsons.org.uk/exena...

“Most of us would agree that disappointing as this may be, this basically puts an end to the hopes that #exenatide or other drugs from the GLP1 agonist class might become the first pharmacotherapeutic approach to slow down progression of #Parkinson.”

x.com/basbloem/status/18461...

[SallyBeeBobs]

Very disappointing.

I was all filled with the optimism and enthusiasm of a PD newbie - I thought it was going to be the wonder drug that would stop PD in its pesky tracks.

Others who have had PD for years have warned of the cynicism that comes after experiencing one disappointment after another. I am starting to see why that would happen.

Thanks for the update, BlockRuys.

[Seamus6]

Ah well not to worry, there'll be something else come along soon that's only "five years away"

In the meantime and if you can, exercise as if your life depends on it - it does.

medicine.yale.edu/news-arti...

[Gioc in reply to Seamus6]

LOL, how much did it cost?

This is already the third failed attempt with this type of substance and there will probably be a fourth.

[BootsOn]

I was told by an "inside source" almost a year ago that it was "looking extremely promising". Hopes were raised and now dashed. I'll be politely enquiring what went wrong next time I see my source.

[JayPwP]

Can it be due to data pooling and averaging of results, that the benefits may be lost in reporting?

[CuriousMe12]

Did it start in 2008?Crazy that these things take so long.

[peminc]

I was watching Neuraly NY001 from afar. It's effectively the same as Exenitide but taken monthly. That failed about a year ago.

My hopes now are on Buntanetap.

[Esperanto]

Very disappointing, of course, given the previous positive results. However, further research into the cause may help us move forward.

The big question might be whether this initial beneficial effect on PD symptoms is due to the drug itself or the significant weight loss experienced by the participants. It’s still unclear, but I suspect there is a connection. Obesity is indeed a known risk factor for PD. Additionally, recent research indicates that caloric restriction may lead to a slowdown of aging processes and the development of PD.

[MarkPrana]

At least we still have Ambroxol going through a Phase 3 trial.

I'm personally quite optimistic about Nicotinamide Riboside, which is at Phase 2 stage - at least for those of us with a mitochondrial-driven form of PD.